Seroprevalence of SARS COV-2 anti-nucleocapsid antibodies in Turkish healthcare workers before vaccination schedule: January 2021
<b>Objective: </b>We aimed to assess the seroprevalence of SARS-CoV-2 infection and associated factors among Turkish HCWs, before the Covid-19 vaccination program in January 2021.<br /> <b>Material and methods: </b>We performed antibody assessment against SARS-CoV-2 in...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
National Scientific Medical Center
2022-06-01
|
| Series: | Ķazaķstannyṇ Klinikalyķ Medicinasy |
| Subjects: | |
| Online Access: | https://www.clinmedkaz.org/download/seroprevalence-of-sars-cov-2-anti-nucleocapsid-antibodies-in-turkish-healthcare-workers-before-12150.pdf |
| _version_ | 1811292057329729536 |
|---|---|
| author | Ayşin Kılınç Toker Ayşe Turunç Özdemir Duygu Çerçioğlu Özdemir Esma Eryilmaz Eren Esma Saatçi İbrahim Toker İlhami Çelik |
| author_facet | Ayşin Kılınç Toker Ayşe Turunç Özdemir Duygu Çerçioğlu Özdemir Esma Eryilmaz Eren Esma Saatçi İbrahim Toker İlhami Çelik |
| author_sort | Ayşin Kılınç Toker |
| collection | DOAJ |
| description | <b>Objective: </b>We aimed to assess the seroprevalence of SARS-CoV-2 infection and associated factors among Turkish HCWs, before the Covid-19 vaccination program in January 2021.<br />
<b>Material and methods: </b>We performed antibody assessment against SARS-CoV-2 in blood samples from participants using the Elecsys® Anti-SARS-CoV-2 electrochemiluminescence immunoassay. Samples with a cut-off index (COI; signal sample/cut-off) <1.0 were considered negative, samples with ≥1.0 were deemed positive.<br />
<b>Results: </b>714 HCWs, 487 women (68.2%), were included in our study. The mean age of the participants was 35.9 ± 8.4 (min:18, max: 62). 370 (51.8%) HCWs's the antibody level was negative, and 344 (48.2%) was positive. While 47.1% (n=122) of the HCWs with positive RT-PCR were antibody positive, 48.8% (n=222) were negative. There was no statistically significant difference in mean age and age groups (p values 0.338 and 0.414, respectively). Also, there was no statistically significant difference in antibody levels by gender (p=0.236). There was no significant difference between antibody positivity according to the presence of comorbidity, and the risk area studied (p=0.556, p=0.335, respectively). There was a statistically significant difference between lung involvement and antibody positivity during Covid-19 infection (p= <0.001).<br />
<b>Conclusion: </b>In our study, the seroprevalence of SARS-CoV-2 antibodies in HCWs was higher than the average population and approximately fifty percent. Multicenter studies with more HCWs would be helpful to determine overall seroprevalence rates. |
| first_indexed | 2024-04-13T04:39:43Z |
| format | Article |
| id | doaj.art-820a0572468940f7ad12b70d708532dd |
| institution | Directory Open Access Journal |
| issn | 1812-2892 2313-1519 |
| language | English |
| last_indexed | 2024-04-13T04:39:43Z |
| publishDate | 2022-06-01 |
| publisher | National Scientific Medical Center |
| record_format | Article |
| series | Ķazaķstannyṇ Klinikalyķ Medicinasy |
| spelling | doaj.art-820a0572468940f7ad12b70d708532dd2022-12-22T03:02:02ZengNational Scientific Medical CenterĶazaķstannyṇ Klinikalyķ Medicinasy1812-28922313-15192022-06-01193656810.23950/jcmk/12150Seroprevalence of SARS COV-2 anti-nucleocapsid antibodies in Turkish healthcare workers before vaccination schedule: January 2021Ayşin Kılınç Toker0Ayşe Turunç Özdemir1Duygu Çerçioğlu Özdemir2Esma Eryilmaz Eren3Esma Saatçi4İbrahim Toker5İlhami Çelik6Department of Infectious Disease and Clinical Microbiology, Kayseri City Hospital, Kayseri, TurkeyDepartment of Infectious Disease and Clinical Microbiology, Kayseri City Hospital, Kayseri, TurkeyDepartment of Infectious Disease and Clinical Microbiology, Kayseri City Hospital, Kayseri, TurkeyDepartment of Infectious Disease and Clinical Microbiology, Kayseri City Hospital, Kayseri, TurkeyDepartment of Medical Microbiology, Kayseri City Hospital, Kayseri, TurkeyDepartment of Emergency Medicine, Kayseri City Hospital, Kayseri, TurkeyDepartment of Infectious Disease and Clinical Microbiology, Kayseri City Hospital, Kayseri, Turkey<b>Objective: </b>We aimed to assess the seroprevalence of SARS-CoV-2 infection and associated factors among Turkish HCWs, before the Covid-19 vaccination program in January 2021.<br /> <b>Material and methods: </b>We performed antibody assessment against SARS-CoV-2 in blood samples from participants using the Elecsys® Anti-SARS-CoV-2 electrochemiluminescence immunoassay. Samples with a cut-off index (COI; signal sample/cut-off) <1.0 were considered negative, samples with ≥1.0 were deemed positive.<br /> <b>Results: </b>714 HCWs, 487 women (68.2%), were included in our study. The mean age of the participants was 35.9 ± 8.4 (min:18, max: 62). 370 (51.8%) HCWs's the antibody level was negative, and 344 (48.2%) was positive. While 47.1% (n=122) of the HCWs with positive RT-PCR were antibody positive, 48.8% (n=222) were negative. There was no statistically significant difference in mean age and age groups (p values 0.338 and 0.414, respectively). Also, there was no statistically significant difference in antibody levels by gender (p=0.236). There was no significant difference between antibody positivity according to the presence of comorbidity, and the risk area studied (p=0.556, p=0.335, respectively). There was a statistically significant difference between lung involvement and antibody positivity during Covid-19 infection (p= <0.001).<br /> <b>Conclusion: </b>In our study, the seroprevalence of SARS-CoV-2 antibodies in HCWs was higher than the average population and approximately fifty percent. Multicenter studies with more HCWs would be helpful to determine overall seroprevalence rates.https://www.clinmedkaz.org/download/seroprevalence-of-sars-cov-2-anti-nucleocapsid-antibodies-in-turkish-healthcare-workers-before-12150.pdfCOVID-19SARS-CoV-2 antibodyhealthcare worker |
| spellingShingle | Ayşin Kılınç Toker Ayşe Turunç Özdemir Duygu Çerçioğlu Özdemir Esma Eryilmaz Eren Esma Saatçi İbrahim Toker İlhami Çelik Seroprevalence of SARS COV-2 anti-nucleocapsid antibodies in Turkish healthcare workers before vaccination schedule: January 2021 Ķazaķstannyṇ Klinikalyķ Medicinasy COVID-19 SARS-CoV-2 antibody healthcare worker |
| title | Seroprevalence of SARS COV-2 anti-nucleocapsid antibodies in Turkish healthcare workers before vaccination schedule: January 2021 |
| title_full | Seroprevalence of SARS COV-2 anti-nucleocapsid antibodies in Turkish healthcare workers before vaccination schedule: January 2021 |
| title_fullStr | Seroprevalence of SARS COV-2 anti-nucleocapsid antibodies in Turkish healthcare workers before vaccination schedule: January 2021 |
| title_full_unstemmed | Seroprevalence of SARS COV-2 anti-nucleocapsid antibodies in Turkish healthcare workers before vaccination schedule: January 2021 |
| title_short | Seroprevalence of SARS COV-2 anti-nucleocapsid antibodies in Turkish healthcare workers before vaccination schedule: January 2021 |
| title_sort | seroprevalence of sars cov 2 anti nucleocapsid antibodies in turkish healthcare workers before vaccination schedule january 2021 |
| topic | COVID-19 SARS-CoV-2 antibody healthcare worker |
| url | https://www.clinmedkaz.org/download/seroprevalence-of-sars-cov-2-anti-nucleocapsid-antibodies-in-turkish-healthcare-workers-before-12150.pdf |
| work_keys_str_mv | AT aysinkılınctoker seroprevalenceofsarscov2antinucleocapsidantibodiesinturkishhealthcareworkersbeforevaccinationschedulejanuary2021 AT ayseturuncozdemir seroprevalenceofsarscov2antinucleocapsidantibodiesinturkishhealthcareworkersbeforevaccinationschedulejanuary2021 AT duygucerciogluozdemir seroprevalenceofsarscov2antinucleocapsidantibodiesinturkishhealthcareworkersbeforevaccinationschedulejanuary2021 AT esmaeryilmazeren seroprevalenceofsarscov2antinucleocapsidantibodiesinturkishhealthcareworkersbeforevaccinationschedulejanuary2021 AT esmasaatci seroprevalenceofsarscov2antinucleocapsidantibodiesinturkishhealthcareworkersbeforevaccinationschedulejanuary2021 AT ibrahimtoker seroprevalenceofsarscov2antinucleocapsidantibodiesinturkishhealthcareworkersbeforevaccinationschedulejanuary2021 AT ilhamicelik seroprevalenceofsarscov2antinucleocapsidantibodiesinturkishhealthcareworkersbeforevaccinationschedulejanuary2021 |